Diseases

Long COVID is defined as “the continuation or development of new symptoms 3 months after the initial SARS-CoV-2 infection, with these symptoms lasting for at least 2 months with no other explanations”, as reported by the World Health Organization. A growing number of people are dealing with a variety of lingering symptoms even after recovering from an acute infection. These can include fatigue, muscle pain, shortness of breath, headaches, cognitive issues, neurodegenerative symptoms, anxiety, depression, and a feeling of hopelessness, and therapeutic options for long COVID are investigated. The potential of hyperbaric oxygen therapy (HBOT) to improve chronic fatigue, cognitive impairments, and neurological disorders has been established; therefore, the use of HBOT to treat long COVID has also been studied. The aim of this literature search is to analyze the state of the art of a potential role of HBOT to improve chronic fatigue, cognitive impairments and neurological disorders. A literature analysis was performed, focusing on the clinical efficacy of HBOT for treating long COVID symptoms. The results from January 2021 to October 2025, using a standard registry database, showed 21 studies, including one case report, ten randomized controlled trial, eight systematic reviews and three studies regarding the molecular mechanism and markers changing after HBOT. They suggested that HBOT can improve quality of life, fatigue, cognition, neuropsychiatric symptoms and cardiopulmonary functions. HBOT is a safe treatment and has shown some benefits for long COVID symptoms. To precisely define indications, protocols, and post-treatment evaluations, we need to conduct more in-depth, large-scale studies.

Introduction: Minor digestive ailments are a common reason for individuals to visit pharmacies, and can be efficiently managed through structured pharmaceutical advice. This study aimed to evaluate the effectiveness of advice provided by pharmacists in community pharmacies from the perspectives of both patients and pharmacists. The primary focus of the study was not on assessing the effectiveness of a specific medication, but rather on the pharmaceutical advice provided. Materials and Methods: This prospective multicenter observational study was conducted between January and March 2025 in community pharmacies across Poland among adult patients with dyspepsia without alarm symptoms and included two visits: an initial visit and a follow-up phone call after 7–14 days. Symptom severity across seven domains was assessed using a GSRS-based tool, and data on adherence, treatment regimen, patient satisfaction, and acceptable costs of the two-visit service were collected. Statistical analyses (p < 0.05) using both parametric and non-parametric tests were performed on data from 100 participants who completed the study, with cost data serving as a proxy for willingness to pay. Results: Most patients (92.7%) reported symptom improvement, with a median time to relief of 3 days and good treatment adherence. The greatest benefits were observed for abdominal pain and flatulence, and higher baseline symptom severity was consistently associated with greater improvement. Service acceptability was high, and patients’ reported willingness to pay suggests perceived value and potential economic feasibility of the service. Conclusions: Structured pharmaceutical advice for digestive ailments (including triage, education, management plans, and monitoring of effects) led to rapid and clinically significant improvements in most patients. This approach demonstrates high adherence rates and positive acceptability. The stability of effects across different demographic groups, along with a predictable pattern of changes in various domains, supports the expansion of this service and customization of educational messages.

Objective: To map and synthesize the published literature on the epidemiological burden of urinary tract infections (UTIs) in adults with spinal cord injury (SCI) or multiple sclerosis (MS) using intermittent catheterization (IC). Methods: We conducted a comprehensive literature review following PRISMA guidelines, searching PubMed, Scopus, and Web of Science for studies published since 2014. A total of 30 studies met the inclusion criteria. Results: Reported UTI incidence varied widely from 24% to 93.1%, highlighting significant heterogeneity across the evidence base. Annually, 15–17% of patients experienced 4–6 UTIs, and up to 16.4% required hospitalization for UTI-related complications. A critical evidence gap was exposed, with only one study focusing specifically on the MS population. Conclusions: Despite its clinical benefits, IC remains underutilized and inconsistently supported. Addressing systemic delivery gaps is essential. UTIs in neurogenic bladder care should be recognized as a modifiable public health issue requiring equity-driven interventions and strengthened implementation frameworks. This review underscores the urgent need for methodologically rigorous research to establish clear best practices.